APA (7th ed.) Citation

Gelderblom, H. R., & Hohenberger, P. (2014). Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European organisation for research and treatment of cancer soft tissue and bone sarcoma group randomised phase II and pharmacogenetic study. European journal of cancer, 50(2), . https://doi.org/10.1016/j.ejca.2013.10.002

Chicago Style (17th ed.) Citation

Gelderblom, Hans R., and Peter Hohenberger. "Brostallicin Versus Doxorubicin as First-line Chemotherapy in Patients with Advanced or Metastatic Soft Tissue Sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Randomised Phase II and Pharmacogenetic Study." European Journal of Cancer 50, no. 2 (2014). https://doi.org/10.1016/j.ejca.2013.10.002.

MLA (9th ed.) Citation

Gelderblom, Hans R., and Peter Hohenberger. "Brostallicin Versus Doxorubicin as First-line Chemotherapy in Patients with Advanced or Metastatic Soft Tissue Sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Randomised Phase II and Pharmacogenetic Study." European Journal of Cancer, vol. 50, no. 2, 2014, https://doi.org/10.1016/j.ejca.2013.10.002.